Table 2 Univariate and multivariate analysis with respect to overall survival in 88 patients with eribulin chemotherapy for locally advanced or metastatic breast cancer

Age at chemotherapy

≤ 63 vs. > 63

0.653

0.366–1.164

0.148

Degree of progress

Locally advanced vs. visceral metastases

0.622

0.328–1.178

0.144

HR (ER and/or PgR)

Positive vs. negative

0.630

0.359–1.107

0.108

HER2

Positive vs. negative

0.366

0.089–1.506

0.164

Ki67

≤ 14% vs. > 14%

1.401

0.803–2.446

0.235

Nuclear grade

1, 2 vs. 3

1.501

0.842–2.673

0.168

Objective response rate

ORR vs. non-ORR

0.310

0.170–0.568

< 0.001

0.321

0.171–0.602

< 0.001

ALCs

≥ 1500/μl vs. < 1500/μl

0.505

0.275–0.926

0.027

0.424

0.138–1.300

0.133

Progression

Progression due to preexisting lesions and high-ALCs vs. others

0.407

0.208–0.795

0.009

0.290

0.091–0.923

0.036

Progression

Progression due to preexisting lesions and low-ALCs vs. others

1.183

0.667–2.097

0.565

Progression

Progression due to new metastasis and high-ALCs vs. others

1.681

0.600–4.712

0.323

Progression

Progression due to new metastasis and low-ALCs vs. others

1.885

1.039–3.422

0.037

1.654

0.846–3.234

0.142